BioPharma Dive Jun 5, 2026 Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
BioPharma Dive Jun 2, 2026 Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
BioPharma Dive Jun 2, 2026 Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
BioPharma Dive Jun 2, 2026 ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer